65 results about "Colistin" patented technology

The invention relates to the fields of analytical chemistry and food safety, particular to a method for detecting the residual quantity of multiple polypeptide veterinary drugs in animal-derived foods. The method comprises the following steps of: processing a sample with a TCA(trichloroacetic acid) and acetonitrile system for depositing proteins; extracting with a carbinol and 0.1% formic acid aqueous solution system; purifying with a Oasis HLB solid phase extraction column; performing gradient elution with an Eclipse XDB-C18 analytical column in the presence of an acetonitrile and 0.1% formic acid aqueous solution used as a mobile phase; and then performing electrospray and positive ion scanning mode separation for finally detecting four polypeptides. The limits of the four polypeptides, namely colistin, bacitracin A, polymyxin B and virginiamycin M, are 25 micrograms/kilogram, 100 micrograms/kilogram, 250 micrograms/kilogram and 120 micrograms/kilogram respectively; the recovery rates of colistin, bacitracin A, polymyxin B and virginiamycin M are 74.9-88.1%, 76.2-89.0%, 76.6-81.2% and 77.3-86.9% respectively; and the coefficients of variation (CV%) of colistin, bacitracin A, polymyxin B and virginiamycin M are 5.7-15.1%, 7.2-15.7%, 6.0-8.0% and 9.5-18.6% respectively. The detection limit, the recovery rate, the accuracy and other technical indexes all meet related detection requirements at home and aboard.

The invention relates to a liquid artificial milk feed, a production method and a feeding device, and the liquid artificial milk feed is characterized in that the formula comprises the following raw materials by weight percent: 4-6% of soy protein concentrate, 4-7% of beef extract, 1-3% of starch, 9-11% of whey powder, 4-7% of pure milk, 0.4-0.6% of calcium hydrogen phosphate, 0.2-0.4% of calciumcarbonate, 0.1-0.2% of common salt, 0.02-0.04% of compound vitamin, 0.1-0.3% of compound trace element, 0.01-0.03% of colistin, 0.01-0.02% of kitasamycin, 0.04-0.06% of bacillus subtilis and the balance of drinking water. The liquid artificial milk feed has the advantage of retarding a series of inadaptations of piglets in the aspects of emergency and a digestive system caused by direct transition from sow milk to powder material during delectation of the piglets. The product can not only meet the nutritional requirements for physiology, growth and development of the piglets, but also realize the scientific and safe transition from the liquid sow milk to the powder material.

The invention discloses a colistin colloidal gold detection kit. The kit mainly comprises a colistin colloidal gold detection test strip, a lyophilized colloidal gold marked colistin specific monoclonal antibody microporous reagent, a microporous panel, a quantitative pipette and a sample diluting liquid, wherein the detection test strip is formed by a PVC back board, a water absorption pad, a sample pad, and a nitrocellulose film (NC film) which is sprayed with a detected antigen coated detection line (T line) and a goat-anti-mouse-anti antibody coated quality control line (C line). The kit is used for detecting colistin residue in eggs or milk without expensive equipment, is simple and convenient to operate, does not need special training, has high detection sensitivity, and is suitablefor wide application in the fields of local laboratories, field detection and the like.

Monoclonal antibodies against bacterial proteins that confer resistance to the antibiotic colistin and hybridomas that produce such monoclonal antibodies are described. The monoclonal antibodies have a strong affinity for MCR proteins and may be used in detection methods and kits to detect the presence of MCR proteins including variants thereof in a sample.

The invention belongs to the technical field of veterinary medicines, and specifically relates to a preparation method for compound tilmicosin enteric-coated granules. The preparation method sequentially comprises the steps of: preparing materials, mixing the materials, granulating, preparing a coating solution, coating and the like, wherein the raw materials of the granules are tilmicosin, colistin, gatifloxacin, a sweetening agent, a flavouring agent, bromhexine hydrochloride, oral glucose, corn starch, saccharose powder, dextrin, talcum powder and starch slurry; the raw materials of the coating solution are HPMC, Tween-80, polyethylene glycol 6000, talcum powder and ethanol. The method disclosed by the invention enables the tilmicosin effective ingredient not to be broken in gastric acid, and to safely arrive at intestinal tracts to be absorbed; the obtained compound tilmicosin enteric-coated granules are capable of preventing and treating respiratory diseases such as mycoplasma diseases, pleuropneumonia and swine plague, capable of reducing the occurrences of bacterial diseases such as diarrhoea and salmonellosis, and capable of increasing the feed conversion.

The invention relates to an oil-in-water type compound colistin nanoemulsion and belongs to the technical field of medicines. The oil-in-water type compound colistin nanoemulsion comprises the following components in parts by weight: 1-18 parts of bitter gourd aqueous extract, 15-40 parts of surfactant, 0-20 parts of cosurfactant, 1-20 parts of colistin, 1-20 parts of oil and 20-70 parts of water. The compound colistin nanoemulsion is narrow in particle size distribution, transparent in system, good in stability, relatively low in surface tension, good in liquidity and easy to take, and the nanoemulsion preparation is used for improving dissolvability and permeability of colistin, so that bioavailability of the medicine is improved; a bitter gourd aqueous extract and the colistin are combined, so that the antibacterial activities of the bitter gourd aqueous extract and the colistin are mutually promoted and enhanced, and the antibacterial effect is more stable.

The invention belongs to the technical field of medicine synthesis, and discloses a method of pure-solid-phase synthesis of polypeptide antibiotic Colistin. By use of the method, the synthetic process and procedure of the Colistin are simplified, the synthesis time is shortened, and the use amount of solvents is reduced.

The invention discloses an oral administration composition of colistin and belongs to the technical field of medicines. The oral administration composition of the colistin is prepared from the following components in parts by weight: 1 part of colistin, 0.01 to 10 parts of absorption promoter and 0 to 100 parts of pharmaceutically acceptable auxiliaries and excipient. In addition, antibacterial drugs are added into a formula, and the addition amount of the antibacterial drugs is one third of therapeutically effective amount. According to the composition, the absorbance of the colistin is greatly improved, the possibility of oral administration treatment for systemic bacterial infection by the colistin is realized; the oral administration composition can replace an injection, so the prejudice of the prior art is overcome. Besides, when the composition contains other antibacterial drugs, a good synergic effect in vivo is realized, and when two thirds of dose of the colistin is reduced, an ideal bacterial infection resisting effect can be still maintained, so that the renal toxicity and the neurotoxicity of the colistin are greatly reduced.

The invention relates to a composition and the preparation method for livestock, poultry and aquatic animals. The virus disease vaccine oral liquid comprises the following materials according to the weight account: loosestrife 12 to 25 parts, humifuse euphorbia 15 to 25 parts, tuber of dwarf lilyturf 10 to 20 parts, phyllanfhus 5 to 20 parts, bitter almond 10 to 25 parts, prunella vulgaris 15 to 25 parts, balloonflower 10 to 20 parts, snake gall 2 to 5 parts, ox gall 10 to 20 parts, aloe 40 to 60 parts, crystal sugar 25 to 40 parts, rimantadine 5 to 10 parts, ribavirin 10 to 15 parts, and colistin 10 to 20 parts. The composition has the advantages of ability to reinforce antibody immunity, to relieve mutual interference among vaccines, and to reinforce the immune effect of the vaccine, and convenient drinking water and administration, high absorptivity, wide distribution, no drug residue or poison or side effect, and wide safety range.

Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical composition which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion that can include sodium citrate, succinic acid, xylitol, glutamic acid, and ethylenediaminetetraacetic acid (EDTA), among others. Additionally disclosed pharmaceutical composition may include API such as antibiotics. Subsequently, the antibiotics agent may be ciprofloxacin, amikacin, tobramycin, colistin methate, or polymixin, among others. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response. Pharmaceutical compositions disclosed may include suitable vehicles which may depend on the dosage form.

The invention discloses a feed for suckling pigs, and relates to the technical field of animal feed. The feed for the suckling pigs is prepared by mixing a base feed and a feed additive, wherein the weight ratio of the base feed to the feed additive is (8-10) to (1-1.5); the feed additive comprises composite multivitamin for suckling pigs, composite multi-minerals for pigs, plant polysaccharide, zinc oxide, lysine, corn flour, baking soda, choline, colistin, ferrous fumarate, an acidifying agent, copper sulfate, fenbendazole, a sweetening agent, an antioxidant, vitamin C, aureomycin, a mould inhibitor and a carrier; the base feed comprises corn, bean pulp, a mixture of rice chaff and husk, cured corn, cured soybeans and fish meal. The feed for the suckling pigs is comprehensive in nutritive value, the palatability of the feed is improved, the feed utilization rate is high, the problems that the suckling pigs are poor in body temperature adjustment capability, are lack of innate immunity, have underdeveloped digestive organs, are not perfect enough in development of cerebral cortex when being born, and the like can be solved, the immunity of the suckling pigs is improved, and the disease resistance of the suckling pigs can be improved.

The invention relates to a poultry and livestock compound medicine containing cinnamon, cherokee rose fruit and colimycin. The poultry and livestock compound medicine comprises cinnamon, cherokee rose fruit and colimycin according to the weight ratio of 1:(20-25):(2-5). The invention also relates to a compound preparation prepared by the poultry and livestock compound medicine. The poultry and livestock compound medicine has the beneficial effects that after proofing by test and study, the cinnamon, cherokee rose fruit and colimycin are jointly used according to special weight ratio; the advantages of obvious synergistic function, quick therapy effect, low cost and the like are realized.

The invention relates to an Acalypha australis L. and colistin-containing compound medicine for livestock and poultry. The compound medicine comprises, by weight, 3-30 parts of colistin and 5-200 parts of Acalypha australis L.. Researches prove that an antibiotic medicine containing Acalypha australis L. can reverse the drug resistance of bacteria to the antibiotic medicine in order to improve the treatment effect of the antibiotic medicine. The compound medicine can be processed through routine methods to prepare powder, a tablet, an oral liquid or a granule, and the compound medicine is added to a livestock and poultry feed according to a main medicine/feed ratio of 0.1-7g/kg to be used for feeding, so the medicine use cost and medicinal residues are greatly reduced, high economic benefits are created for farmers, and the food safety is ensured.

The present invention relates to a synergistic pharmacological association of NAC and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected from S. maltophilia and A. baumannii strains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising CF, bronchiectasis non CF and COPD.

The invention belongs to the technical field of synthetic antibiotic extraction and purification, and particularly relates to a method for preparing polymyxin sodium methanesulfonate by a crystallization process, which comprises the following steps: (1) reacting colistin, formaldehyde and sodium hydrogen sulfite under certain conditions to obtain a polymyxin sodium methanesulfonate solution, and drying to obtain a polymyxin sodium methanesulfonate crude product; (2) stirring and dissolving the polymyxin sodium methanesulfonate crude product in a solvent A at 30-45 DEG C for 0.5-5 hours according to a mass volume ratio of the polymyxin sodium methanesulfonate crude product to the solvent A of 1: (3-10), preserving heat and filtering to obtain insoluble substance sodium salt, thereby obtaining filtrate; (3) slowly cooling the filtrate to 0-20 DEG C, then adding a poor solvent B with a volume of 20-50% of the filtrate volume, and carrying out stirring crystallization at the rotating speed of 20-60 r/min for 0.5-3 h; and (4) filtering, and drying a filter cake to obtain the polymyxin sodium methanesulfonate. The method has the advantages of short steps, simple operation and high yield, and is suitable for commercial popularization and production.

The invention discloses a traditional Chinese medicine active ingredient targeted screening method and a kit. According to the targeted screening method, a traditional Chinese medicine active ingredient targeted screening medium is based on ultrahigh affinity acting force between an inactive mutant CL7 of colistin E7 DNA enzyme and homologous immune protein Im7 of the inactive mutant CL7; therefore, one-step reversible immobilization of fusion of the CL7 label in the cell lysis solution and the GPCRs is realized, and thus the targeted screening method integrates ultrahigh affinity between Im7and CL7 and high specificity of receptor recognition drugs, and high-specificity targeted rapid screening of GPCRs targeted traditional Chinese medicine active ingredients can be realized.

The invention relates to a compound medicine containing licorice roots and colistin for livestock and poultry. The compound medicine is composed of licorice roots and colistin, and the weight ratio of licorice roots to colistin ranges from 1:3 to 1:10. The invention is further required to protect a compound preparation prepared through the compound medicine for the livestock and poultry. The compound medicine has the advantages of being obvious in synergistic effect, quick in curative effect, low in cost and the like by using colistin and licorice roots according to the specific weight ratio in a combined mode through an experimental study.